No Data
Ascendis Pharma Is Maintained at Outperform by Wedbush
Ascendis Pharma Is Maintained at Outperform by Evercore ISI Group
Ascendis Pharma Analyst Ratings
Express News | Ascendis Pharma A/S : Leerink Partners Raises Target Price to $200 From $190
RBC Raises Price Target on Ascendis Pharma to $210 From $205, Keeps Outperform, Speculative Risk
Wedbush Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $212